Phase 4 study of Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection

Trial Profile

Phase 4 study of Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection

Planning
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Seizures
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Dec 2016 New trial record
    • 04 Dec 2016 According to a Sunovion media release, information about this study relevant to the recruitment of potential investigators will be available at the Sunovion Scientific Exhibit at the 70th Annual Meeting of the American Epileptic Society (AES).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top